Why This Diagnosis Deserves More Attention
PA Buchi Neita opens by asking his guest, Lisa Weiss, PA-C, why chronic hand eczema (CHE) warrants a dedicated conversation. Weiss frames it as a debilitating and under-recognized disease state that dermatology sees far more often than it gets credit for. She cites a lifetime prevalence of nearly 15%, with roughly 10% affected in a given year of adult life, and notes that moderate to severe disease affects about a third of the patients clinicians encounter.
Weiss emphasizes the real-world toll. CHE is common in women, often tied to occupational and domestic exposures, and can directly limit a patient's productivity and ability to earn a living. She points to preschool teachers, chefs and food service workers, people in the metal industries, nannies, and stay-at-home moms washing bottles and pump parts as frequent cases. Neita adds that healthcare providers are prime candidates because of constant handwashing and sanitizer use.
Knowing the Subtypes — and Why Most Patients Have More Than One
Weiss walks through the three main subtypes. Irritant contact dermatitis is the most common, accounting for roughly 40% of CHE, driven by prolonged, repeated exposure to water, detergents, and solvents that disrupt the skin barrier — no true contact allergen required. Neita highlights a classic clinical scenario: a rash under a wedding band that patients assume is a metal allergy but is actually irritant contact from soap and water trapped under the ring. Weiss's counseling tip is to lift the ring after handwashing and dry underneath.
Allergic contact dermatitis is driven by a relevant contact allergen, which is why patch testing matters. Atopic hand eczema shows up in patients with atopic dermatitis elsewhere, so Weiss stresses asking whether patients have eczema anywhere else on the body — and remembering that atopic patients have a disrupted barrier that predisposes them to irritant contact.
Her biggest teaching point: more than 50% of CHE cases involve overlapping subtypes. Weiss cautions against forcing the diagnosis into a single box. A patient may be allergic to something while also carrying an atopic or irritant component underneath. That makes a deep history — occupation, exposures, emollient use, what they contact daily — central to the diagnosis.
When to Patch Test and What Clues to Watch For
Weiss contrasts the European approach, which favors patch testing everyone to identify a true allergen before treating, with the U.S. approach she agrees with: patch test when a known allergen is suspected, but don't delay treatment waiting on results. She notes in-office panels may not cover every allergen, and access to more extensive testing can take months or even years. The priority is getting symptomatic patients better quickly.
Neita raises MI/MCI (methylisothiazolinone) as a common allergen, and notes patients who remove it may still have residual rash from the irritant component. Weiss adds nickel, fragrance, formaldehyde, and gold as frequent findings — with gold being a tough conversation for patients attached to their jewelry (she mentions dipping rings in platinum as an option).
On morphology clues, Weiss says signs help sometimes and mislead other times. She notes hyperkeratotic hand eczema is correlated with smoking and more common in men — a point she uses to motivate smoking cessation when hands are the patient's chief concern. Vesicular presentations and bad fingertips make her think irritant contact first, but overlapping subtypes often blur the picture.
Treatment: Barrier First, Then Topicals and a New Option
Weiss is firm that barrier protection and emollients are the mainstays regardless of what she prescribes. She recommends true physical barriers — gloves with white cotton interiors, and the long 'old granny dish gloves' up to the elbow — for anyone with heavy water exposure. Neita paints the picture for patients: don't touch a fork in the sink without gloves. Both stress switching away from harsh, fragranced hand soaps and being mindful of hand sanitizer overuse, which spiked post-COVID. Weiss also advises healthcare workers to wash less often and moisturize immediately after every wash.
For active disease, Weiss still starts with high-potency topical steroids, most commonly in ointment form, to quickly control inflammation. She then transitions to nonsteroidals like tacrolimus or pimecrolimus as a good steroid steward for safer long-term control.
The newer option is delgocitinib, described as the only FDA-approved treatment for CHE, approved for moderate to severe disease. It's a twice-daily, nonsteroidal pan-JAK inhibitor with no black box warning. Weiss reports strong real-world efficacy—even better than the stringent clinical study endpoints suggested—and shares a preschool teacher who said her hands no longer hurt when washing just seven days after starting. She attributes the drug's success to its ability to target the overlapping subtypes from multiple angles, and she has been using it with good luck for painful fissures as well.